Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
St. Francis Hospital and Heart Center, Roslyn, NY, USA.
Ann Surg Oncol. 2022 Sep;29(9):5555-5563. doi: 10.1245/s10434-022-11626-w. Epub 2022 Apr 30.
Oncocytic adrenocortical neoplasms (OANs) are rare endocrine tumors that present as a spectrum from benign to malignant. The outcomes after surgical resection of the oncocytic variant of adrenocortical carcinoma remain poorly understood. We sought to characterize the clinicopathologic features of OAN and compare oncocytic adrenocortical carcinoma (OAC) with conventional adrenocortical carcinoma (ACC).
Adult patients who underwent adrenalectomy for OAN or ACC between January 1990 and September 2020 were identified. Demographics, clinicopathologic factors, American Joint Committee on Cancer stage, and cancer-related outcomes were reviewed. A matched cohort analysis of disease-free survival (DFS) and overall survival (OS) was performed between patients with OACs and those with ACCs.
Forty-one patients with OAN and 214 patients with ACC were included. The OAN cohort median age was 45.2 years [interquartile ratio (IQR) 38.5-54.0 years], and 61.0% were female. OANs were benign (n = 11), of uncertain malignant potential (UMP, n = 9), or OAC (n = 21). Disease recurrence occurred in 12 (57.1%) patients with OAC compared with 1 (11.1%) and 0 patients with UMP or benign OAN, respectively (p < 0.001). Seven (33.3%) patients with OAC died during follow-up compared with 0 patients with UMP or benign OAN (p = 0.020). Kaplan-Meier survival analysis found no difference in DFS between ACC and OAC groups before (p = 0.218) and after 2:1 matching (p = 0.417). Overall survival was shorter for patients who had ACC compared with those who had OAC (p = 0.031), but the difference was not evident with matched analysis (p = 0.200).
OAN presents as a spectrum from benign indolent tumors to aggressive carcinomas. OACs demonstrate similar clinicopathologic behavior and recurrence-free and overall survival when matched to conventional ACCs.
嗜酸细胞瘤性肾上腺皮质肿瘤(OAN)是一种罕见的内分泌肿瘤,其表现从良性到恶性。目前对于手术切除嗜酸细胞瘤性肾上腺皮质癌的效果仍知之甚少。我们旨在研究 OAN 的临床病理特征,并比较嗜酸细胞瘤性肾上腺皮质癌(OAC)与常规肾上腺皮质癌(ACC)。
我们确定了 1990 年 1 月至 2020 年 9 月期间因 OAN 或 ACC 接受肾上腺切除术的成年患者。回顾了人口统计学、临床病理因素、美国癌症联合委员会分期和癌症相关结局。对 OAC 患者和 ACC 患者的无病生存率(DFS)和总生存率(OS)进行了匹配队列分析。
共纳入 41 例 OAN 患者和 214 例 ACC 患者。OAN 队列的中位年龄为 45.2 岁[四分位间距(IQR)38.5-54.0 岁],61.0%为女性。OAN 为良性(n=11)、恶性潜能不确定(UMP,n=9)或 OAC(n=21)。与 UMP 或良性 OAN 患者相比,OAC 患者的疾病复发率为 12 例(57.1%),分别为 1 例(11.1%)和 0 例(p<0.001)。在随访期间,OAC 患者中有 7 例(33.3%)死亡,而 UMP 或良性 OAN 患者中无一例死亡(p=0.020)。Kaplan-Meier 生存分析显示,在未匹配(p=0.218)和 2:1 匹配后(p=0.417),ACC 和 OAC 组之间的 DFS 无差异。与 OAC 患者相比,ACC 患者的总生存率较低(p=0.031),但匹配分析后差异并不明显(p=0.200)。
OAN 表现为良性惰性肿瘤至侵袭性癌的一系列表现。OAC 与常规 ACC 相匹配时,具有相似的临床病理行为、无复发和总生存率。